Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Mega Cap Growth ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Vanguard Mega Cap Growth ETF trades at $90.02. Which is the better fit depends on your goals.
| BBIO | MGK | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $90.17 | $92.06 |
52-Week Low | $47.29 | $70.70 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
MGK, the Vanguard Mega Cap Growth ETF, trades at $90.79, up 0.87% on the day, with a bullish technical signal driven by strong moving average alignment. The ETF's concentrated portfolio of 69 large-cap U.S. growth stocks, heavily weighted toward technology and consumer discretionary sectors, has delivered robust historical returns. Recent news highlights its low 0.05% expense ratio and potential inclusion of high-profile stocks like SpaceX, reinforcing its appeal for growth-oriented investors seeking mega-cap exposure.
The outlook for MGK remains positive due to its focus on leading growth companies, but risks include high concentration in tech stocks and sensitivity to market volatility. Investors benefit from cost efficiency and historical outperformance, yet must monitor sector-specific downturns and valuation pressures. The ETF is suited for long-term growth strategies with tolerance for drawdowns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
